Research programme: cardiovascular disease therapies - Sagene Pharmaceuticals

Drug Profile

Research programme: cardiovascular disease therapies - Sagene Pharmaceuticals

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sagene Pharmaceuticals
  • Class Antithrombotics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders; Thrombosis

Most Recent Events

  • 28 Feb 2018 Preclinical development is ongoing for cardiovascular disorders and thrombosis in USA (Sagene Pharmaceuticals pipeline, February 2018)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top